• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miR-193b的下调有助于增强人乳腺癌中尿激酶型纤溶酶原激活剂(uPA)的表达以及肿瘤进展和侵袭。

Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.

作者信息

Li X-F, Yan P-J, Shao Z-M

机构信息

Breast Cancer Institute, Department of Breast Surgery, Cancer Hospital/Cancer Institute, Shanghai Medical College, Institutes of Biomedical Sciences, Fudan University, Shanghai, PR China.

出版信息

Oncogene. 2009 Nov 5;28(44):3937-48. doi: 10.1038/onc.2009.245. Epub 2009 Aug 24.

DOI:10.1038/onc.2009.245
PMID:19701247
Abstract

Emerging evidence suggests the potential involvement of altered regulation of miRNAs in the pathogenesis of cancers, and these miRNAs are thought to be functional as tumor suppressors or oncogenes. Using miRNA arrays, we identified an miRNA differentially expressed between the MDA-MB-231 cell line and its highly metastatic variant. A bioinformatics search revealed a potential target site for miR-193b within the 3'UTR of uPA. Ectopic expression of miR-193b repressed the expression of sensor constructs harboring the 3'UTR of uPA in breast cancer cell lines. Anti-miR-193b treatment led to an increase of uPA protein and increased cell invasion in MDA-MB-231 cells. In contrast, overexpression of miR-193b significantly reduced uPA protein amounts and inhibited cell invasion in MDA-MB-231 and MDA-MB-435 cells. In an immunodeficient mouse model, miR-193b significantly inhibited the growth and dissemination of xenograft tumors. Immunohistochemical staining and real-time PCR assays showed that miR-193b was a negative regulator of the uPA gene in primary breast tumors. Our research reveals that miR-193b is closely associated with clinical metastasis and identifies miR-193b potentially targets uPA transcripts. Perturbation of the miRNA-mRNA pairing may have important roles in the initiation and development of breast cancer.

摘要

新出现的证据表明,微小RNA(miRNA)调控异常可能参与癌症的发病机制,并且这些miRNA被认为具有肿瘤抑制因子或癌基因的功能。利用miRNA芯片,我们鉴定出一种在MDA-MB-231细胞系及其高转移变体之间差异表达的miRNA。生物信息学搜索揭示了尿激酶型纤溶酶原激活物(uPA)的3'非翻译区(3'UTR)内存在miR-193b的一个潜在靶位点。miR-193b的异位表达抑制了乳腺癌细胞系中含有uPA的3'UTR的报告基因构建体的表达。抗miR-193b处理导致MDA-MB-231细胞中uPA蛋白增加并增强细胞侵袭。相反,miR-193b的过表达显著降低了MDA-MB-231和MDA-MB-435细胞中uPA蛋白的量并抑制细胞侵袭。在免疫缺陷小鼠模型中,miR-193b显著抑制异种移植肿瘤的生长和扩散。免疫组织化学染色和实时定量PCR分析表明,miR-193b是原发性乳腺肿瘤中uPA基因的负调节因子。我们的研究揭示miR-193b与临床转移密切相关,并确定miR-193b可能靶向uPA转录本。miRNA与mRNA配对的扰动可能在乳腺癌的发生和发展中起重要作用。

相似文献

1
Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.miR-193b的下调有助于增强人乳腺癌中尿激酶型纤溶酶原激活剂(uPA)的表达以及肿瘤进展和侵袭。
Oncogene. 2009 Nov 5;28(44):3937-48. doi: 10.1038/onc.2009.245. Epub 2009 Aug 24.
2
Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.降钙素抑制乳腺癌细胞的侵袭:尿激酶型纤溶酶原激活剂(uPA)及uPA受体的作用
Int J Oncol. 2006 Apr;28(4):807-14.
3
Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines.蛋白质裂解物微阵列分析以鉴定调节乳腺癌细胞系中雌激素受体信号传导的微小RNA。
Oncogene. 2009 Nov 5;28(44):3926-36. doi: 10.1038/onc.2009.241. Epub 2009 Aug 17.
4
Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).可溶性尿激酶型纤溶酶原激活物受体(CD87)过表达可减少乳腺癌肿瘤生长及肺转移。
Cancer Gene Ther. 2000 Feb;7(2):292-9. doi: 10.1038/sj.cgt.7700144.
5
Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22.通过 microRNA miR-22 控制转移性乳腺癌细胞中的 EVI-1 癌基因表达。
Oncogene. 2011 Mar 17;30(11):1290-301. doi: 10.1038/onc.2010.510. Epub 2010 Nov 8.
6
MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells.微小RNA-23b介导尿激酶和c-甲硫氨酸下调以及人肝癌细胞迁移能力降低。
FEBS J. 2009 Jun;276(11):2966-82. doi: 10.1111/j.1742-4658.2009.07014.x. Epub 2009 Apr 16.
7
Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.使用uPA基因敲除和免疫缺陷异种移植联合模型,获得关于基质尿激酶型纤溶酶原激活剂(uPA)在实验性人类乳腺癌生长中重要性的直接证据。
Cancer Res. 2001 Jan 15;61(2):532-7.
8
Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.用于测定乳腺癌患者原发肿瘤组织中尿激酶型纤溶酶原激活剂和纤溶酶原激活剂抑制剂1 mRNA的定量逆转录聚合酶链反应检测:与酶联免疫吸附测定法进行抗原定量的比较
Int J Mol Med. 2008 Feb;21(2):251-9.
9
Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.骨桥蛋白可诱导人乳腺上皮细胞的侵袭性增加及纤溶酶原激活物表达上调。
Oncogene. 1999 Jul 22;18(29):4237-46. doi: 10.1038/sj.onc.1202799.
10
CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer.CFTR 通过靶向前列腺癌细胞中的尿激酶型纤溶酶原激活物(uPA)抑制 miR-193b 的表达来抑制肿瘤的进展。
Oncogene. 2013 May 2;32(18):2282-91, 2291.e1-7. doi: 10.1038/onc.2012.251. Epub 2012 Jul 16.

引用本文的文献

1
miR-193b-3p suppresses lung cancer cell migration and invasion through PRNP targeting.miR-193b-3p通过靶向PRNP抑制肺癌细胞的迁移和侵袭。
J Biomed Sci. 2025 Feb 20;32(1):28. doi: 10.1186/s12929-025-01121-1.
2
Deciphering molecular landscape of breast cancer progression and insights from functional genomics and therapeutic explorations followed by in vitro validation.解析乳腺癌进展的分子特征,并通过体外验证对功能基因组学和治疗探索的深入了解。
Sci Rep. 2024 Nov 20;14(1):28794. doi: 10.1038/s41598-024-80455-6.
3
Identification of exosomal microRNAs and related hub genes associated with imatinib resistance in chronic myeloid leukemia.
鉴定与慢性髓性白血病伊马替尼耐药相关的外泌体 microRNAs 和相关枢纽基因。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Dec;397(12):9701-9721. doi: 10.1007/s00210-024-03198-1. Epub 2024 Jun 25.
4
Exploring the intricate relationship between miRNA dysregulation and breast cancer development: insights into the impact of environmental chemicals.探讨 miRNA 失调与乳腺癌发展之间错综复杂的关系:环境化学物质影响的洞察。
Front Immunol. 2024 May 14;15:1333563. doi: 10.3389/fimmu.2024.1333563. eCollection 2024.
5
Posttranscriptional Regulation of the Plasminogen Activation System by Non-Coding RNA in Cancer.非编码 RNA 对癌症纤溶酶原激活系统的转录后调控
Int J Mol Sci. 2023 Jan 4;24(2):962. doi: 10.3390/ijms24020962.
6
MiR-193b as an effective biomarker in human cancer prognosis for Asian patients: a meta-analysis.MiR-193b作为亚洲患者人类癌症预后的有效生物标志物:一项荟萃分析。
Transl Cancer Res. 2022 Jul;11(7):2249-2261. doi: 10.21037/tcr-21-2557.
7
Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer.雌激素受体生物活性决定了雌激素受体阳性乳腺癌的临床内分泌治疗选择。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221090351. doi: 10.1177/15330338221090351.
8
MiR-193b-5p inhibits proliferation and enhances radio-sensitivity by downregulating the AKT/mTOR signaling pathway in tongue cancer.微小RNA-193b-5p通过下调舌癌中的AKT/mTOR信号通路来抑制增殖并增强放射敏感性。
Transl Cancer Res. 2020 Mar;9(3):1851-1860. doi: 10.21037/tcr.2020.02.14.
9
Associations between the Levels of Estradiol-, Progesterone-, and Testosterone-Sensitive MiRNAs and Main Clinicopathologic Features of Breast Cancer.雌二醇、孕酮和睾酮敏感型微小RNA水平与乳腺癌主要临床病理特征之间的关联
J Pers Med. 2021 Dec 21;12(1):4. doi: 10.3390/jpm12010004.
10
Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.miR-193b 通过调控 WNT/β-catenin、c-Met 和整合素信号通路的协同作用,控制三阴性乳腺癌的转移特性。
BMC Cancer. 2021 Dec 4;21(1):1296. doi: 10.1186/s12885-021-08955-6.